Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Lenvatinib in Chinese Patients with Solid Tumors
NCT03009292Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib in solid tumor, sponsored by Eisai Co., Ltd. Primary endpoints: Area under the concentration-time curve over the dosing interval on multiple dosing at Day 16, Time at which the highest drug concentration occurs at steady-state at Day 16 and 6 more. Started Aug 2018; status: completed.
02
Drugs
lenvatinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03009292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03009292.